Earnings Call

Fresh off its IPO, Bill Ackman's firm is ditching the exclusive call for open X Spaces Q&As. A signal of radical transparency or a new compliance risk?

As Enghouse readies its Q2 results, investors are watching a split narrative: a struggling contact center arm versus a growing assets division, all while the firm sits on a massive cash pile.

Hormel Foods declared its 392nd dividend, but a high payout ratio and lagging stock have investors weighing its legendary reliability against current risks.

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

After a record stock plunge, Planet Fitness is under investigation for misleading investors with rosy forecasts that masked serious operational headwinds.

The ticket marketplace saw revenue fall year-over-year, but a surge in cash flow and sequential growth offers a potential path to recovery.

As Sachem Capital sets its Q1 earnings date, investors watch closely for signs of stability in the hard money lending market after a volatile period.

Aon reports a robust start to 2026 with 5% organic growth and a 332% jump in free cash flow, underscoring the success of its integrated strategy.

MPS smashes Q1 revenue records, fueled by a 98% surge in its AI data segment. The company now eyes a massive $6 billion capacity expansion.

Activist investor Trian Fund Management launches a public campaign against Solventum, alleging massive value destruction and excessive executive compensation.

Philip Morris International's upcoming Q1 2026 earnings will be a crucial test of its pivot from cigarettes, with all eyes on ZYN's growth and regulatory hurdles.

As TI preps its Q1 2026 earnings call, all eyes are on its performance as an indicator for the industrial, auto, and broader semiconductor sectors.

As Milestone Scientific prepares its year-end call, investors look for signs of a turnaround and growth for its advanced injection technology.

The midstream firm is refinancing debt and buying back preferred units, aiming for a simpler, more flexible financial future. What does this mean for NGL?

After a 39% stock crash, Lakeland Industries' former CFO is sued over allegedly misleading investors about the company's deteriorating financial health.

FinVolution Group is set to release its 2025 financials, with investors watching to see if international growth and AI tech can navigate market headwinds.

Fresh off a blockbuster IPO, SpyGlass Pharma heads to a key investor summit. Can its revolutionary long-acting drug platform transform chronic eye care?

The spirits giant faces a steep sales decline and a massive write-down, pivoting to premium brands and operational fixes amid an industry-wide hangover.

Beam Therapeutics is set to announce its 2025 financial results and a new liver-targeted therapy, a key moment for its base editing platform and investors.

With a novel skin drug launched, Pelthos Therapeutics heads to a key conference. Can its focused strategy convince Wall Street of its blockbuster potential?